All In Biotech

Drug Trial Radar · NCT00627640

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine

Last checked: Nov 19, 2026Latest source record: Mar 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 549 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

549

Actual

Start

Feb 2009

Primary completion

Jan 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Newron Pharmaceuticals SPAIndustry
Sponsor type
Industry
First posted
Mar 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the major DA metabolising enzyme in man. Safinamide is an inhibitor of MAO-B. This is a phase III trial to evaluate the efficacy and safety of safinamide (50 and 100 mg p.o. q.a.m.) compared to placebo as add-on therapy to a stable dose to levodopa in subjects with advance idiopathic Parkinson's Disease. The principal efficacy measure is the increase in mean daily "on" time during the 18-hr diary recording period.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

  • Safinimide 50-100 mg/dayDrug

    Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative

  • Matching PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the change from baseline to W24 in daily "on" time ("on" time without dyskinesia plus "on" time with minor dyskinesia)Time frame: 24 weeks

Locations

121 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • San Francisco Clinical Research Center

    San Francisco, California

  • Parkinson's Institute

    Sunnyvale, California

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • Parkinson's Disease and Movement Disorder Center

    Boca Raton, Florida

  • Neurologic Consultants P.A.

    Fort Lauderdale, Florida

  • University of Florida

    Gainesville, Florida

  • Parkinson's Disease Treatment Center of SW Florida

    Port Charlotte, Florida

  • Neurology Clinical Research Inc.

    Sunrise, Florida

  • University Of South Florida Medical Center

    Tampa, Florida

  • Wesley Woods Geriatric Center

    Atlanta, Georgia

  • Columbus Research Institute

    Columbus, Georgia

  • Northwestern University PD and Movement Disorders Center

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Boston University School of Medicine

    Boston, Massachusetts

  • Quest Research Institute

    Bingham Farms, Michigan

  • Parkinson's Disease and Movement Disorder Center

    Albany, New York

  • North Shore Medical Center

    Manhasset, New York

  • Neurological Institute of New York

    New York, New York

  • The Neurological Institute

    Charlotte, North Carolina

  • Duke Movement Disorders Clinic

    Durham, North Carolina

  • Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • Concord Repatriation General Hospital

    Concord, Australia

  • Central Coast Neuroscience Research

    East Gosford, Australia

  • Univ.Klinik Graz

    Graz, Austria

  • Univ.Klinik Innsbruck

    Innsbruck, Austria

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • U.Z Antwerpen

    Edegem, Belgium

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, Belgium

  • ZNA Hoge Beuken

    Hoboken, Belgium

  • Heilig Hart Roeselare - Campus westlaan

    Roeselare, Belgium

  • AZ Sint-Augustinus

    Wilrijk, Belgium

  • King David

    Halifax, Canada

  • Kingston General Hospital

    Kingston, Canada

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.